Relmada Therapeutics (RLMD) Stock Price

Relmada Therapeutics Price

NASDAQ·CLOSED
4.73USD+0.19 (+4.10 %)
Market closed

Revenue at Relmada Therapeutics has contracted by 28.4% per year over the past 2 years to 5,129.00 USD. For Relmada Therapeutics, the net margin of -877.7% is down versus -100.0% a few years ago. The consensus 12-month price target for Relmada Therapeutics is 9.18 USD, about 94.1% above where the stock trades today. Of 9 analysts, 8 rate the stock a buy — an overall Buy consensus. The stock trades about 675% above its 52-week low.

Relmada Therapeutics stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Relmada Therapeutics over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Relmada Therapeutics stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Relmada Therapeutics's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Relmada Therapeutics Stock Price History
DateRelmada Therapeutics Price
8/12/20264.73 USD
8/10/20264.54 USD
8/7/20264.94 USD
8/6/20265.37 USD
8/5/20265.35 USD
8/4/20265.54 USD
8/3/20265.30 USD
7/31/20265.31 USD
7/30/20265.35 USD
7/29/20265.13 USD
7/27/20265.23 USD
7/23/20265.20 USD
7/22/20265.00 USD
7/21/20265.30 USD
7/20/20265.00 USD
7/17/20265.24 USD
7/16/20265.46 USD
7/15/20266.21 USD
7/14/20266.21 USD
7/13/20266.47 USD
7/10/20266.41 USD
7/9/20266.51 USD
7/8/20266.66 USD
7/7/20266.41 USD
7/6/20266.40 USD
7/2/20266.28 USD
7/1/20266.39 USD
6/30/20266.92 USD
6/29/20266.98 USD
6/26/20266.69 USD
6/25/20266.45 USD
6/24/20266.51 USD
6/23/20266.77 USD
6/22/20266.71 USD
6/18/20266.55 USD
6/17/20266.80 USD
6/16/20266.55 USD
6/15/20266.89 USD
6/12/20266.78 USD
6/11/20266.50 USD
6/10/20266.57 USD
6/9/20266.27 USD
6/8/20265.72 USD
6/5/20265.95 USD
6/4/20266.31 USD
6/3/20266.33 USD
6/2/20266.42 USD
6/1/20266.85 USD
5/29/20267.21 USD
5/28/20267.25 USD
5/27/20267.26 USD
5/26/20267.17 USD
5/22/20267.04 USD
5/21/20267.21 USD
5/20/20267.17 USD
5/19/20267.03 USD
5/18/20266.34 USD
5/15/20266.90 USD
5/14/20267.42 USD
5/13/20267.49 USD
5/12/20267.45 USD
5/11/20267.36 USD
5/8/20267.32 USD
5/7/20267.43 USD
5/6/20267.86 USD
5/5/20267.35 USD
5/4/20267.41 USD
5/1/20267.64 USD
4/30/20267.52 USD
4/29/20267.37 USD
4/28/20267.24 USD
4/27/20267.03 USD
4/24/20267.21 USD
4/23/20267.25 USD
4/22/20267.06 USD
4/21/20267.14 USD
4/20/20267.37 USD
4/17/20267.48 USD
4/16/20267.00 USD
4/15/20267.18 USD
4/14/20267.19 USD
4/13/20267.38 USD
4/10/20267.29 USD
4/9/20267.61 USD
4/8/20267.01 USD
4/7/20266.75 USD
4/6/20266.90 USD
4/2/20266.99 USD
4/1/20267.10 USD
3/31/20266.96 USD
3/30/20266.38 USD
3/27/20266.43 USD
3/26/20266.53 USD
3/25/20266.66 USD
3/24/20266.10 USD
3/23/20265.86 USD
3/20/20266.07 USD
3/19/20266.25 USD
3/18/20266.21 USD
3/17/20266.45 USD
3/16/20266.18 USD
3/13/20265.91 USD
3/12/20266.15 USD
3/11/20266.32 USD
3/10/20266.62 USD
3/9/20267.17 USD
3/6/20264.45 USD
3/5/20264.43 USD
3/4/20264.77 USD
3/3/20264.67 USD
3/2/20264.84 USD
2/27/20264.56 USD
2/26/20264.60 USD
2/25/20264.55 USD
2/24/20264.26 USD
2/23/20264.03 USD
2/20/20264.13 USD
2/19/20264.36 USD
2/18/20264.08 USD
2/17/20263.64 USD
2/13/20263.72 USD
2/12/20263.90 USD
2/11/20264.00 USD
2/10/20264.02 USD
2/9/20264.20 USD
2/6/20263.88 USD
2/5/20263.60 USD
2/4/20263.65 USD
2/3/20263.80 USD
2/2/20263.83 USD
1/30/20263.55 USD
1/29/20263.91 USD
1/28/20263.95 USD
1/27/20264.10 USD
1/26/20263.97 USD
1/23/20263.90 USD
1/22/20263.96 USD
1/21/20263.81 USD
1/20/20263.94 USD
1/16/20263.74 USD
1/15/20263.80 USD
1/14/20263.84 USD
1/13/20264.06 USD
1/12/20264.11 USD
1/9/20264.31 USD
1/8/20264.43 USD
1/7/20264.32 USD
1/6/20264.08 USD
1/5/20264.23 USD
1/2/20264.37 USD
12/31/20254.83 USD
12/30/20254.53 USD
12/29/20254.45 USD
12/26/20254.51 USD
12/24/20254.60 USD
12/23/20254.49 USD
12/22/20254.49 USD
12/19/20254.35 USD
12/18/20254.15 USD
12/17/20254.01 USD
12/16/20254.50 USD
12/15/20254.36 USD
12/12/20254.06 USD
12/11/20254.19 USD
12/10/20254.42 USD
12/9/20254.14 USD
12/8/20254.17 USD
12/5/20254.24 USD
12/4/20254.00 USD
12/3/20254.06 USD
12/2/20254.04 USD
12/1/20254.42 USD
11/28/20254.51 USD
11/26/20254.19 USD
11/25/20254.26 USD
11/24/20254.30 USD
11/21/20254.27 USD
11/20/20254.32 USD
11/19/20254.18 USD
11/18/20254.27 USD
11/17/20253.97 USD
11/14/20253.95 USD
11/13/20253.88 USD
11/12/20253.91 USD
11/11/20253.29 USD
11/10/20253.01 USD
11/7/20252.65 USD
11/6/20252.61 USD
11/5/20252.51 USD
11/4/20252.77 USD
11/3/20252.20 USD
10/31/20252.26 USD
10/30/20252.32 USD
10/29/20252.45 USD
10/28/20252.45 USD
10/27/20252.33 USD
10/24/20252.10 USD
10/23/20252.21 USD
10/22/20252.14 USD
10/21/20252.24 USD
10/20/20252.26 USD
10/17/20252.01 USD
10/16/20252.01 USD
10/15/20252.07 USD
10/14/20251.93 USD
10/13/20252.02 USD
10/10/20252.04 USD
10/9/20252.20 USD
10/8/20252.13 USD
10/7/20251.99 USD
10/6/20252.08 USD
10/3/20252.32 USD
10/2/20252.66 USD
10/1/20252.16 USD
9/30/20252.01 USD
9/29/20251.88 USD
9/26/20251.81 USD
9/25/20251.66 USD
9/24/20251.65 USD
9/23/20251.67 USD
9/22/20251.65 USD
9/19/20251.53 USD
9/18/20251.65 USD
9/17/20251.51 USD
9/16/20251.60 USD
9/15/20251.67 USD
9/12/20251.59 USD
9/11/20251.52 USD
9/10/20251.61 USD
9/9/20251.56 USD
9/8/20251.60 USD
9/5/20251.65 USD
9/4/20251.37 USD
9/3/20251.47 USD
9/2/20251.42 USD
8/29/20251.12 USD
8/28/20250.77 USD
8/27/20250.67 USD
8/26/20250.66 USD
8/25/20250.62 USD
8/22/20250.63 USD
8/21/20250.61 USD
8/20/20250.61 USD
8/19/20250.62 USD
8/18/20250.66 USD
8/15/20250.65 USD
Access this data via the Eulerpool API
Get Free API Key

Relmada Therapeutics Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
0.00 USD
-103.70 M USD
-98.79 M USD
Jan 1, 2024
0.00 USD
-83.89 M USD
-79.98 M USD
Jan 1, 2025
0.00 USD
-59.10 M USD
-57.39 M USD
Jan 1, 2026 (e)
10.00 M USD
-54.84 M USD
-24.94 M USD
Jan 1, 2027 (e)
32.45 M USD
-89.18 M USD
-29.11 M USD
Jan 1, 2028 (e)
12.67 M USD
-103.73 M USD
-28.58 M USD
Jan 1, 2029 (e)
66.30 M USD
-124.33 M USD
-22.92 M USD
Jan 1, 2030 (e)
134.41 M USD
-73.69 M USD
-12.52 M USD

Relmada Therapeutics Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 15, 2026, 4:25 AM
 
REVENUEM USD
REVENUE GROWTH%
EBITM USD
EBIT MARGIN%
NET INCOMEM USD
NET INCOME GROWTH%
SHARESM
201520162017201820192020202120222023202420252026e2027e2028e2029e2030e
–––––––––––10.0032.0012.0066.00134.00
––––––––––––220.00-62.50450.00103.03
-17.00-16.00-7.00-6.00-15.00-60.00-125.00-161.00-103.00-83.00-59.00-54.00-89.00-103.00-124.00-73.00
–––––––––––-540.00-278.13-858.33-187.88-54.48
-20.00-2.00-6.00-8.00-15.00-59.00-125.00-157.00-98.00-79.00-57.00-24.00-29.00-28.00-22.00-12.00
–-90.00200.0033.3387.50293.33111.8625.60-37.58-19.39-27.85-57.8920.83-3.45-21.43-45.45
2.863.013.146.4011.3716.2619.0830.1030.1030.1768.2668.2668.2668.2668.2668.26
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Relmada Therapeutics generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Relmada Therapeutics retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Relmada Therapeutics's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Relmada Therapeutics has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Relmada Therapeutics's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Relmada Therapeutics stock margins

The Relmada Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Relmada Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Relmada Therapeutics.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
21.31 %
- %
- %
Jan 1, 2022
21.31 %
- %
- %
Jan 1, 2023
21.31 %
- %
- %
Jan 1, 2024
21.31 %
- %
- %
Jan 1, 2025
21.31 %
- %
- %
Jan 1, 2026 (e)
21.31 %
-548.42 %
-249.36 %
Jan 1, 2027 (e)
21.31 %
-274.83 %
-89.70 %
Jan 1, 2028 (e)
21.31 %
-818.95 %
-225.63 %

Relmada Therapeutics Stock Revenue, EBIT, Earnings per Share

The Relmada Therapeutics earnings per share therefore indicates how much revenue Relmada Therapeutics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
0.00 USD
-6.59 USD
-6.59 USD
Jan 1, 2022
0.00 USD
-5.36 USD
-5.22 USD
Jan 1, 2023
0.00 USD
-3.45 USD
-3.28 USD
Jan 1, 2024
0.00 USD
-2.78 USD
-2.65 USD
Jan 1, 2025
0.00 USD
-0.87 USD
-0.84 USD
Jan 1, 2026 (e)
0.33 USD
-0.80 USD
-0.83 USD
Jan 1, 2027 (e)
1.08 USD
-1.31 USD
-0.97 USD
Jan 1, 2028 (e)
0.42 USD
-1.52 USD
-0.95 USD

Relmada Therapeutics business model & stock analysis

Relmada Therapeutics Inc is a biopharmaceutical company specializing in the development of medications for a variety of chronic pain and mental health disorders. The company is headquartered in New York, USA, and was founded in 2004. The history of Relmada Therapeutics Inc began with a focus on the development of NMDA receptor antagonists for the treatment of neuropathic pain. The company's main drug, d-Methadone, has been successfully tested in a Phase IIa clinical study and is now being tested in Phase IIb studies. Relmada Therapeutics Inc's business model is based on the development and commercialization of novel drugs targeting high medical needs. The company has a strong pipeline of pharmaceutical products in various clinical phases that can be used in pain management and mental health promotion. Relmada Therapeutics Inc generates revenue through the sale of patents and the out-licensing of their products to other pharmaceutical companies. In addition, the company pursues partnerships and joint ventures with other companies to further develop and market their products. Relmada Therapeutics Inc operates in three main divisions: pain therapy, mental health, and oncology. In pain therapy, the company has its main products, such as Oral Methadone and LevoCap ER, which help patients alleviate chronic pain. LevoCap ER is a long-acting, non-addictive pain medication that increases effectiveness and safety compared to other opioids. In the mental health field, Relmada Therapeutics Inc has developed QN-19, an overactive NMDA receptor blocker that represents a potential treatment option for depressive disorders. The company has also developed its new technology platform, mGluR2/3 agonists, which can be used in the treatment of anxiety and depression. In the oncology division, the company focuses on the development of innovative cancer treatments. The company is currently developing a new cancer drug that aims to overcome chemotherapy resistance. Relmada Therapeutics Inc is committed to providing innovative solutions to improve and enhance the quality of life for patients. The company relies on a strong research and development platform to develop medications targeting a variety of needs. The company is committed to continuing its research and development to provide innovative solutions that improve the treatment of chronic diseases. Answer: Relmada Therapeutics Inc is a biopharmaceutical company specializing in the development of medications for chronic pain and mental health disorders. The company is headquartered in New York, USA, and has a strong pipeline of pharmaceutical products in various clinical phases. They generate revenue through the sale of patents and partnerships with other companies, and their divisions focus on pain therapy, mental health, and oncology. They aim to provide innovative solutions to improve patient quality of life and continue research and development for better treatment options.

Relmada Therapeutics SWOT Analysis

Strengths

Relmada Therapeutics Inc has several strengths that contribute to its competitive advantage:

  • Strong portfolio of innovative pharmaceutical products
  • Advanced research and development capabilities
  • Experienced and knowledgeable team of professionals
  • Strong financial position and access to funding
  • Established partnerships with key industry players

Weaknesses

Despite its strengths, Relmada Therapeutics Inc also faces certain weaknesses that could hinder its growth:

  • Limited market presence and brand recognition
  • Relatively small size compared to industry giants
  • Dependence on a few key products for revenue generation
  • Potential regulatory hurdles and challenges
  • High research and development costs

Opportunities

Relmada Therapeutics Inc can leverage the following opportunities to expand its business:

  • Increasing demand for innovative pharmaceutical solutions
  • New market entry possibilities and global expansion
  • Collaboration and partnerships with academic institutions and research organizations
  • Advancements in technology that support drug development
  • Growing focus on mental health and neurological disorders

Threats

Relmada Therapeutics Inc needs to be aware of the following threats that could negatively impact its business:

  • Intense competition from established pharmaceutical companies
  • Potential entry of generic drug manufacturers
  • Stringent regulatory requirements and compliance
  • Changing market dynamics and trends
  • Risks associated with clinical trials and drug development processes

Relmada Therapeutics Employees

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Relmada Therapeutics Employees
Details
Date
Relmada Therapeutics Employees
Jan 1, 2018
- Employees
Jan 1, 2019
- Employees
Jan 1, 2020
- Employees
Jan 1, 2021
- Employees
Jan 1, 2022
- Employees
Jan 1, 2023
- Employees
Jan 1, 2024
- Employees
Jan 1, 2025
- Employees

Relmada Therapeutics Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Relmada Therapeutics historical P/E ratio, EBIT multiple, and P/S ratio

Relmada Therapeutics annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Relmada Therapeutics shares outstanding

The number of shares of Relmada Therapeutics was 68.26 M in 2025. This indicates how many shares Relmada Therapeutics is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
19.08 M Stocks
Jan 1, 2022
30.10 M Stocks
Jan 1, 2023
30.10 M Stocks
Jan 1, 2024
30.17 M Stocks
Jan 1, 2025
68.26 M Stocks
Jan 1, 2026 (e)
68.26 M Stocks
Jan 1, 2027 (e)
68.26 M Stocks
Jan 1, 2028 (e)
68.26 M Stocks

Relmada Therapeutics stock splits

In Relmada Therapeutics's history, there have been no stock splits.

Current Relmada Therapeutics forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
10.00 %
Buy
88.89 % (8)
Hold
11.11 % (1)
Sell
0.00 % (0)
12M Price Target
9.18
Last Price
4.73
Currency
USD
12M Return Potential
94.08 %
LTM Return
0 %

Relmada Therapeutics Analyst Rating Actions

DateFirmActionRatingReliability
3/20/2026
Mizuho
Mizuho
MaintainedOutperform31
1/23/2026
Leerink Partners
Leerink Partners
UpgradeMarket PerformOutperform–
11/19/2025
Mizuho
Mizuho
UpgradeNeutralOutperform31
12/5/2024
Mizuho
Mizuho
DowngradeOutperformNeutral31
12/4/2024
Leerink Partners
Leerink Partners
DowngradeOutperformMarket Perform–
6/5/2024
Goldman Sachs
Goldman Sachs
DowngradeNeutralSell–
6/15/2023
Mizuho
Mizuho
MaintainedBuy31
1/23/2023
SVB Leerink
SVB Leerink
MaintainedOutperform–
10/14/2022
Guggenheim
Guggenheim
DowngradeBuyNeutral30
10/14/2022
Goldman Sachs
Goldman Sachs
DowngradeBuyNeutral–

Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.

Relmada Therapeutics Earnings Calls

2025

Relmada Therapeutics Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
8/6/2026-0.20USD-0.00USD-2026 Q2
5/13/2026-0.20USD-0.00USD-2026 Q1
3/24/2026-0.14USD-0.00USD-2025 Q4
11/13/2025-0.12USD-0.00USD-2025 Q3
11/7/2024-0.59USD-0.00USD-2024 Q3
5/9/2024-0.99USD-0.00USD-2024 Q1
3/21/2024-0.85USD-0.00USD-2023 Q4
11/8/2023-0.86USD-0.00USD-2023 Q3
8/9/2023-1.41USD-0.00USD-2023 Q2
5/3/2023-1.44USD-0.00USD-2023 Q1

EESG©

Eulerpool ESG Scorecard© for the Relmada Therapeutics stock

48/100
48
Environment
80
Social
17
Governance
E

Environment

20
Scope 1 - Direct Emissions—
Scope 2 - Indirect emissions from purchased energy—
Scope 3 - Indirect emissions within the value chain—
Total CO₂ emissions—
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees60
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Relmada Therapeutics shareholder structure

% Name
24.66339%
Janus Henderson Investors
Janus Henderson Investors
14.15604%
Adage Capital Management, L.P.
Adage Capital Management, L.P.
13.54664%
Spruce Street Capital LP
Spruce Street Capital LP
10.57447%
Marshall Wace LLP
Marshall Wace LLP
10.17232%
Ikarian Capital LLC
Ikarian Capital LLC
8.65475%
OrbiMed Advisors, LLC
OrbiMed Advisors, LLC
...

Relmada Therapeutics Beneficial Ownership Filings (SEC 13D/G)

Free Float
86.2%
Float Shares
-
Shares Outstanding
-
StakeHolderFiling
10.70%
C. Conway
C. Conway
SEC ↗
10.10%
JANUS HENDERSON GROUP PLC
JANUS HENDERSON GROUP PLC
SEC ↗
9.90%
Squadron Master Fund LP
Squadron Master Fund LP
SEC ↗
9.31%
RTW Investments, LP
RTW Investments, LP
SEC ↗
9.31%
Roderick Wong
Roderick Wong
SEC ↗
8.57%
Eun Sun Uh
Eun Sun Uh
SEC ↗
8.25%
Deep Track Capital, LP
Deep Track Capital, LP
SEC ↗
8.25%
Deep Track Biotechnology Master Fund, Ltd.
Deep Track Biotechnology Master Fund, Ltd.
SEC ↗
8.25%
David Kroin
David Kroin
SEC ↗
8.20%
VHCP Management II, LLC
VHCP Management II, LLC
SEC ↗

Relmada Therapeutics Executives and Management Board

8 members · avg. age 64 · 13 % women

ST

Mr. Sergio Traversa (64)

Chief Executive Officer, Director · since 2012

1.80 M USD

Management

MS

Mr. Maged Shenouda (60)

Chief Financial Officer · since 2015

993,750.00 USD
CE

Mr. Charles Ence (65)

Chief Accounting, Compliance Officer

983,039.00 USD
PK

Mr. Paul Kelly (66)

Chief Operating Officer, Director · since 2015

872,780.00 USD
TM

Mr. Tim McCarthy

Investor Relations · since 2020

–

Board of Directors

CC

Mr. Charles Casamento (78)

Independent Chairman of the Board

353,608.00 USD
FF

Ms. Fabiana Fedeli (54)

Independent Director

290,638.00 USD
JG

Mr. John Glasspool (62)

Independent Director

286,518.00 USD

Relmada Therapeutics Supply Chain

Relmada Therapeutics Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
1 companies
#NameTrend
1
WONPUNG MULSAN
Supplier·Customer·Textiles, Apparel & Luxury Goods·KR
0.30
0.36
0.16
-0.08
0.59
0.80

Frequently asked questions about Relmada Therapeutics

Relmada Therapeutics Inc is a pharmaceutical company that focuses on developing and commercializing innovative therapies for various medical conditions. Their business model revolves around researching and developing novel drug candidates, acquiring intellectual property rights, conducting clinical trials, and seeking regulatory approvals for their innovative products. By leveraging their expertise in drug development, Relmada aims to address unmet medical needs and improve patients' quality of life. Through collaborations and strategic partnerships, the company strives to bring their innovative therapies to market and generate value for their stakeholders.

Relmada Therapeutics Inc is primarily active in the pharmaceutical and biotechnology industries.

The main competitors of Relmada Therapeutics Inc in the market include companies such as Johnson & Johnson, Pfizer Inc, Novartis AG, and Eli Lilly and Company.

Relmada Therapeutics Inc is a pharmaceutical company specializing in the development and commercialization of novel therapies for various diseases. Founded in 2012, Relmada focuses on innovative solutions to address unmet medical needs and improve patients' lives. The company's research and development efforts primarily concentrate on central nervous system (CNS) disorders, including chronic pain, addiction, and rare diseases. Relmada Therapeutics Inc has successfully advanced several promising drug candidates through preclinical and clinical trials, demonstrating its commitment to delivering effective and safe treatments. With its dedication to scientific advancements, Relmada Therapeutics Inc is poised to make a significant impact in the evolving healthcare industry.

Relmada Therapeutics Inc has achieved several significant milestones. The company successfully completed Phase 2 trials for its lead product, d-Methadone, for the treatment of neuropathic pain. In addition, Relmada Therapeutics received Fast Track designation from the U.S. Food and Drug Administration (FDA) for d-Methadone, which expedites the development and review process. The company also completed a successful IPO, raising $65 million in gross proceeds. Relmada Therapeutics continues to advance its pipeline, focusing on innovative therapies for central nervous system (CNS) disorders. With its groundbreaking achievements, Relmada Therapeutics Inc has positioned itself as a key player in the pharmaceutical industry.

Relmada Therapeutics Inc primarily operates in the United States.

Relmada Therapeutics Inc represents values of innovation, commitment to patient wellbeing, and scientific excellence. The company is dedicated to developing novel therapies to address unmet medical needs. Relmada focuses on advancing research and developing cutting-edge treatments to improve patients' quality of life. Their corporate philosophy revolves around collaboration, ethical practices, and a patient-centric approach. Relmada Therapeutics Inc believes in fostering partnerships and leveraging scientific expertise to create transformative healthcare solutions. Through their dedication to innovation and commitment to advancing medical science, Relmada aims to make a meaningful impact in improving patient outcomes and addressing global healthcare challenges.

Analysts currently set an average price target of 9.18 USD for the Relmada Therapeutics stock (median: 9.18 USD), implying +94.1 % versus the latest price. The consensus is based on 9 analyst ratings.

Relmada Therapeutics Analyst Price Targets 2026

9 analysts currently rate the Relmada Therapeutics stock: 8 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Relmada Therapeutics to generate revenue of 10.00 M USD and earnings per share of -0.37 USD.

Relmada Therapeutics Analyst Price Targets 2026

Converted at the current exchange rate, the Relmada Therapeutics share trades at 4.09 EUR (4.73 USD).

The Relmada Therapeutics share (RLMD) is listed on 3 stock exchanges, including: NASDAQ (RLMD), Frankfurt (4E2.F), München (4E2.MU).

Relmada Therapeutics Inc. is a biopharmaceutical company specializing in the development of novel therapeutics for central nervous system (CNS) disorders. The company is headquartered in New York City and offers a wide range of products and services tailored to the needs of patients and medical professionals. Relmada Therapeutics' business model is based on identifying, developing, and marketing innovative therapeutics for brain disorders and other psychiatric illnesses. The company holds a number of patents for developing biological therapeutics targeting various molecules within the human body. It has established an extensive network of partnerships with leading scientific and medical institutions to conduct a variety of clinical studies that help demonstrate the efficacy and safety of its products. Relmada Therapeutics' portfolio includes a range of novel therapeutics that can be used to treat a variety of psychiatric disorders. The company specializes in the development of preparations for the treatment of pain, depression, and addiction. Its flagship product is REL-1017, which targets the glutamatergic receptor and is currently in phase 3 clinical trials for the treatment of depression. In addition to its product pipeline, Relmada Therapeutics also offers a comprehensive range of services for medical professionals and patients. The company has a team of experienced clinical experts who assist customers in developing individualized treatment plans tailored to the specific needs of each patient. Relmada Therapeutics has also built a wide range of partnerships and alliances with key players in the pharmaceutical industry and healthcare. These partnerships enable the company to further expand its product development activities and improve the global marketing of its therapeutics. Overall, Relmada Therapeutics is an innovative biopharmaceutical company focused on improving the treatment of psychiatric disorders. Its comprehensive portfolio of products and services for medical professionals and patients, its experienced clinical experts, and its strong partnerships with other key players in the industry make it a significant player in the global market for psychiatric medications.

The expected revenue of Relmada Therapeutics is 10.00 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Relmada Therapeutics is -24.94 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Relmada Therapeutics is currently -12.95. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Relmada Therapeutics stock.

The price-to-sales ratio (P/S) of Relmada Therapeutics is currently 32.28. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Relmada Therapeutics stock.

The Eulerpool Quality Score for Relmada Therapeutics is 2/10.

The ISIN of Relmada Therapeutics is US75955J4022. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Relmada Therapeutics is A2PSZF. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Relmada Therapeutics is RLMD. The ticker symbol is used to trade Relmada Therapeutics shares on the stock exchange.

Relmada Therapeutics paid dividends every year for the past 0 years.

Relmada Therapeutics is assigned to the 'Health' sector.

The dividends of Relmada Therapeutics are distributed in USD.

All fundamentals and in-depth analysis of Relmada Therapeutics

Our stock analysis for Relmada Therapeutics stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Relmada Therapeutics. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Relmada Therapeutics Stock
Relmada Therapeutics Revenue→
Relmada Therapeutics Stock
Relmada Therapeutics Net Income→
Relmada Therapeutics Stock
Relmada Therapeutics P/E→
Relmada Therapeutics Stock
Relmada Therapeutics P/S→
Relmada Therapeutics Stock
Relmada Therapeutics EBIT→
Relmada Therapeutics Stock
Relmada Therapeutics Dividend→
Relmada Therapeutics Stock
Relmada Therapeutics Directors Dealings→
Relmada Therapeutics Stock
Relmada Therapeutics Stocks→
Relmada Therapeutics Stock
Relmada Therapeutics Market capitalization→
Relmada Therapeutics Stock
Relmada Therapeutics Debt→
Relmada Therapeutics Stock
Relmada Therapeutics Liabilities→
Relmada Therapeutics Stock
Relmada Therapeutics Equity→
Relmada Therapeutics Stock
Relmada Therapeutics AAQS→
Relmada Therapeutics Stock
Relmada Therapeutics Employees→
Relmada Therapeutics Stock
Relmada Therapeutics ROE→
Relmada Therapeutics Stock
Relmada Therapeutics ROA→
Relmada Therapeutics Stock
Relmada Therapeutics ROCE→
Relmada Therapeutics Stock
Relmada Therapeutics News→
Relmada Therapeutics Stock
Relmada Therapeutics Analyst Price Targets→

Health Stocks

Remed CoRelay TherapeuticsRemedentRekah Pharmaceutical IndustryRemeGen CoRein TherapeuticsRemeGen CoRegis HealthcareREMSleep HoldingsRegenxbioRemus PharmaceuticalsRegeneRx BiopharmaceuticalsAll Stocks A–Z →